AstraZeneca is in talks with relevant authorities on a trade name and is currently referring to the treatment by its generic name, vandetanib.
AstraZeneca Specialty Care vice president Lisa Schoenberg said vandetanib is the only medicine specifically approved for patients with this rare form of cancer.